Amgen Data on T-Vec to Be Published This Week

Data for Amgen’s talimogene laherparepvec (T-VEC) in advanced melanoma is among many abstracts that will be published ahead of the American Society of Clinical Oncology (ASCO) annual meeting. Abstracts will be available on May 15 at 6 p.m. ET.

Click here to continue reading

Bloomberg BRIEF Newsletters